{
    "nctId": "NCT04669873",
    "briefTitle": "Accelerated Partial Breast Irradiation Versus Standard or Hypofractionated Whole-Breast Irradiation, in Early Breast Cancer, After Breast-conserving Surgery",
    "officialTitle": "Clinical Trial, Randomized, Open Label, With an Active Comparator to Assess the Efficacy and Safety of Using Accelerated Partial Irradiation Versus Standard or Hypofractionated Irradiation of the Entire Breast in Patients With Initial Breast Cancer After Conservative Surgery",
    "overallStatus": "RECRUITING",
    "conditions": "Malignant Neoplasm of Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 36,
    "primaryOutcomeMeasure": "Rate of local recurrence",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Information to the patient and signed informed consent;\n* Women aged \u226550 years\n* Breast conserving surgery\n* Pathologic tumor size \\< 3 cm (maximum microscopic diameter of the invasive component)\n* Invasive adenocarcinoma (except classic invasive lobular carcinoma)\n* Unifocal disease\n* Histopathologic grades I or II\n* Eastern Cooperative Oncology Group (ECOG) 0-1\n* Lymphovascular invasion absent\n* Negative axillary lymph nodes\n* Minimum microscopic margins of non-cancerous tissue of 2mm (excluding deep margin when in deep fascia)\n* No prior breast or mediastinal radiotherapy\n* No hematogenous metastases\n\nExclusion Criteria:\n\n* Previous malignancy (except non-melanomatous skin cancer)\n* Mastectomy\n* Classical-Type Invasive Lobular Carcinoma\n* Neoadjuvant chemotherapy\n* Human Epidermal growth factor Receptor-type 2 positive (HER2+)\n* Triple-negative breast cancers\n* Intravascular lymphoma present\n* Contraindications to radiotherapy.\n* No geographical, social or psychologic reasons that would prevent study follow",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}